KEYNOTE SPEAKERS
Prof. Daniel Trifiletti,
Mayo Clinic in Florida
Professor Daniel Trifiletti is a radiation oncologist at the Mayo Clinic in Florida.
His research interests focus on the role of radiation in priming the brain tumour microenvironment, exploring the synergy between radiation and novel cellular therapies; and identifying novel indications for intracranial functional radiosurgery.
A/Prof. Sarah Olson,
Princess Alexandra Hospital in Brisbane Australia
Associate Professor Olson is a neurosurgeon at Princess Alexandra Hospital in Brisbane, Australia. She specialises in functional neurosurgery, neurooncology, pituitary surgery and Gamma knife treatment. A/Prof Olson is one of the first Australian neurosurgeons to utilise laser interstitial thermal therapy (LITT), a novel technique to treat brain tumors that are difficult to treat with other modalities. She is the past president of the neurosurgery society of Australasia and is the surgical education and training board chair for neurosurgery.
Prof. Mark Bilsky,
Memorial Sloan Kettering Cancer Center & Weill Medical College of Cornell University, New York City
Professor Mark Bilsky is an Attending Neurosurgeon at Memorial Sloan Kettering Cancer Center and Professor of Neurological Surgery at Weill Medical College of Cornell University. He holds the William E. Snee Endowed Chair in Neurosurgical Spine Oncology and is Chief of the MSKCC Multi-disciplinary Spine Tumor Service. Dr. Bilsky’s clinical practice and research efforts are focused on the multi-modality treatment of both metastatic and primary malignant and benign spine and spinal cord tumors. This effort has led to the development of the NOMS decision framework which provides a platform to integrate evidence-based medicine and new technologies into treatment paradigms for spine tumors. Dr. Bilsky is one of the leading voices on the rational integration of stereotactic radiosurgery and the development of minimally invasive surgical techniques leading to over 250 publications and 500 invited lectureships.
OTHER KEY PRESENTERS
Dr Chris Harper,
GenesisCare Wembley and
Sir Charles Gairdner Hospital, Perth
Dr Chris Harper completed his initial training in Western Australia before undertaking post-graduate studies in the UK, Canada, and the USA. He is the medical director at GenesisCare Wembley and holds a clinical staff position at Sir Charles Gairdner Hospital. Chris has experience in many advanced radiation therapy techniques including stereotactic radiosurgery, stereotactic body radiation therapy, episcleral plaque brachytherapy for choroidal melanoma, and image guided radiation therapy, including IMRT. Chris was a board member of the Faculty of Radiation Oncology of the RANZCR and has also been a guest editor for the International Journal of Stereotactic Radiosurgery. Chris’ key clinical interests include neuro-oncology (brain, skull base and ocular tumours) and neurological and Stereotactic Radiosurgery. Chris is interested in research relating to predominantly intracranial, spinal, prostate, and lung tumours.
Dr Katrina Morris,
Royal North Shore & Concord RG Hospitals, Sydney
Dr Morris is a neurologist with specialty interest in neuromuscular disease and neuro-oncology. After neurology training in Sydney she was awarded the ANZAN fellowship to John Radcliffe Hospital in Oxford completing a fellowship in the NF2 unit in Oxford, and a PhD focused on the UK specialty service's experience of treating people with Bevacizumab.
Dr Morris is a member of the multidisciplinary NF clinic in clinical genetics at Royal North Shore Hospital, Sydney where she cares for people with schwannomatosis (Nf2 related and other) and NF1. Katrina also consults at Concord RG Hospital, in a large clinic for (mainly genetic) muscle and nerve disease at Concord RG Hospital. The shared needs of these two groups and the search for new targeted therapies are what keep her excited to bring evidence-based care, patient reported outcomes and biomarkers into the clinic for day to day monitoring and care throughout all phases of life, particularly for people with NF and schwannomatosis.
Dr Cecelia De Gzell,
Icon Cancer Centres, Sydney
Dr Cecelia Gzell is an experienced Radiation Oncologist who consults and treats patients at multiple Icon Cancer Centre locations across Sydney’s outer-metro area. Dr Gzell completed a postgraduate Neuro-Oncology fellowship at Royal North Shore Hospital, followed by a PhD, and maintains a strong interest in clinical research and education. She was a board member for the International Stereotactic Radiosurgery Society (ISRS, 2022-2024) and is currently the ISRS Treasurer and Chair of the ISRS Congress for 2026 in Sydney. A founding member of the Stereotactic Interest Group of Australasia (SIGA), Cecelia also has a longstanding relationship with the Co-operative Trials Group for Neuro-Oncology (COGNO) and is a senior lecturer at Australian National University (ANU).
A/Prof Nick Hardcastle,
Peter MacCallum Cancer Centre, Melbourne
A/Prof Hardcastle is a Medical Physicist, and Research Lead for Physical Sciences at Peter MacCallum Cancer Centre. Nick’s clinical expertise and research interests lie in use of imaging in radiation oncology, radiation therapy treatment planning, and stereotactic ablative body radiation therapy. Nick is active in the ESTRO Re-irradiation physics working group, interested in quantifying and reducing dose mapping uncertainties.